Gritstone Grabs $92.7m To Test Personalized Vaccines In Humans

 
• By Mandy Jackson

Gritstone closed a Series B venture capital financing to advance its immunotherapy based on cancer patients' own neoantigens into clinical testing and to explore a new shared antigen platform.

Innovation concept presented by a consultant in management on webinar screen

More from Immuno-oncology

More from Anticancer